Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T-ALL-iPSC in vivo  

作　　者：Weiran Li Meiling Zhou Lu Wang Liying Huang Xuemei Chen Xizhuo Sun Tao Liu 

机构地区：[1]Department of Tumor Immunotherapy,Shenzhen Luohu People's Hospital,The Third Affiliated Hospital of Shenzhen University,Shenzhen,Guangdong,China [2]Cell Quality Testing Laboratory of Shenzhen Luohu Hospital Group,Shenzhen,Guangdong,China

出　　处：《Cancer Innovation》2024年第1期50-60,共11页肿瘤创新（英文）

基　　金：Science,Technology and Innovation Commission of Shenzhen Municipality,Grant/Award Number:CYJ20170412155231633;Health Commission of Shenzhen Municipality,Grant/Award Number:SZXK062。

摘　　要：Background:Since RNA sequencing has shown that induced pluripotent stem cells(iPSCs)share a common antigen profile with tumor cells,cancer vaccines that focus on iPSCs have made promising progress in recent years.Previously,we showed that iPSCs derived from leukemic cells of patients with primary T cell acute lymphoblastic leukemia(T-ALL)have a gene expression profile similar to that of T-ALL cell lines.Methods:Mice with T-ALL were treated with dendritic and T(DC-T)cells loaded with intact and complete antigens from T-ALL-derived iPSCs(T-ALL-iPSCs).We evaluated the safety and antitumor efficiency of autologous tumor-derived iPSC antigens by flow cytometry,cytokine release assay,acute toxicity experiments,long-term toxicity experiments,and other methods.Results:Our results indicate that complete tumor antigens from T-ALL-iPSCs could inhibit the growth of inoculated tumors in immunocompromised mice without causing acute and long-term toxicity.Conclusion:T-ALL-iPSC-based treatment is safe and can be used as a potential strategy for leukemia immunotherapy.

关 键 词：adoptive cell therapy drug safety evaluation IPSCS T-ALL 

分 类 号：R730.5[医药卫生—肿瘤]